Request Trial
flaming-torch-in-ice
1 January 2012BiotechnologyMaryAnne Armstrong

Is there life for medical diagnostic patents after Prometheus?

On March 20, 2012, the US Supreme Court handed down the long-awaited decision in Mayo Collaborative Services v Prometheus Laboratories Inc. The Prometheus decision rocked the IP world and left people wondering whether there is any room left for patents in the medical diagnostic industry, particularly as it applies to personalised medicine.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Novartis bets $2bn on biologics as Xolair patents fade
27 March 2026   The Swiss pharma giant targets next-generation anti-IgE biologics as it looks to extend its dominance in the market.
Biotechnology
mRNA litigation: Who’s winning, who’s filing, and what’s next
25 March 2026   As the world moves past the pandemic, a massive legal struggle over the future of mRNA technology is just hitting its stride. LSIPR visualises the litigation defining the next era.
Biotechnology
‘Doing more with less’: In-house counsel on budgets and strategy
22 October 2025   Chuck Scholtz, head of IP at Verdiva Bio, shares the pressures of global filing strategies on tight budgets, why there’s no ‘right way’ to manage IP, and how to get the best results from external counsel relationships.


Editor's picks

Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market
Americas
Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market
1 April 2026

Editor's picks

Americas
Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market
1 April 2026
Biotechnology
mRNA litigation: Who’s winning, who’s filing, and what’s next
25 March 2026
Americas
Masimo convinces judge that Apple took secrets—but it’s not enough
19 March 2026
Americas
Abbott IP chief: ‘Firms without AI policies scare me’
5 March 2026
Americas
LSPN Awards 2026 finalists revealed
2 March 2026
Americas
SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
26 February 2026

More features

UPC refuses early knockout in Illumina–Element dispute
Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market
IndiaMart v CDSCO: A test of intermediary liability
UPC appeals court upholds Abbott injunction in glucose monitoring patent dispute
CRISPR priority feud ends at USPTO as board reaches decision
Novartis bets $2bn on biologics as Xolair patents fade
WIPR debuts Global In-House Elite 2026
mRNA litigation: Who’s winning, who’s filing, and what’s next